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Background. Trastuzumab improves survival in HER2-positive women with metastatic breast cancer (MBC). The consequences
of longer survival include a higher likelihood of additional metastases, including those in the central nervous system (CNS). The
eﬀect of CNS metastases on both trastuzumab discontinuation and survival in older patients has not been described. Patients
and Methods. We used the Surveillance Epidemiology and End Results (SEER) Medicare data to identify a cohort of 562 women
age 66 or older with MBC who were diagnosed between January 1, 2000 and December 31, 2005, free of CNS metastases, and
initiated trastuzumab after MBC diagnosis. Time to discontinuation and time to death were analyzed using proportional hazards
models. Results. Newly diagnosed CNS metastases were associated with both higher risk of trastuzumab discontinuation (relative
hazard [RH] = 1.78, 95% CI 1.11–2.87) and higher risk of death (RH = 2.49, 95% CI 1.84–3.37). The incidence rate of new CNS
metastases was comparable among various sites of metastasis (10.7 to 14.7 per 1,000 patient-months), except for bone which was
higher (24.1 per 1,000). Conclusion. The diagnosis of CNS metastases was associated with an increase in both the likelihood of
discontinuing trastuzumab therapy as well as the risk of death.
1.Introduction
Central nervous system (CNS) metastases are common com-
plications after the development of metastatic breast cancer
(MBC), occurring in up to 15% of such patients accord-
ing to observational data [1–4]. Autopsy studies show rates
as high as 30% overall, which suggests that a substantial
proportion is clinically undetected [5]. In addition, patients
with human epidermal growth factor receptor-2 (HER2)
positive disease who receive trastuzumab may have lifetime
rates of CNS metastases as high as 50% [3].
In HER2-positive MBC, trastuzumab is indicated for use
in combination with paclitaxel for ﬁrst-line treatment, and
as a single agent for patients who previously received at
least one chemotherapy regimen [6]. While the safety and
eﬃcacy of trastuzumab have been evaluated in many clinical
trials of women with MBC [7–15], less is known about the
epidemiology of metastases in older HER2-positive popu-
lations whoaremorelikely to havelessaggressivedisease and
who are less well represented in trials.
Trastuzumab is associated with a signiﬁcant improve-
ment in mortality, changing the natural history of the
disease and allowing patients to live longer. Because CNS
metastases tend to appear later in the course of metastatic
disease [16], the development of CNS metastases represents
a growing challenge in the treatment of MBC, including
possiblyaﬀectingdecisionsaboutdiscontinuationoftherapy.
Therefore, it is important to understand and quantify the
extent to which the incidence of CNS metastases leads to
treatment discontinuation [17].2 Journal of Cancer Epidemiology
The purpose of this study was to evaluate factors associ-
ated with discontinuation of therapy and with outcomes in
HER2-positive older women with metastatic disease treated
with trastuzumab. In particular, we sought to determine
whether the newly diagnosed CNS metastases might aﬀect
both discontinuation of trastuzumab as well as mortality. A
secondary objective was to identify other factors associated
with discontinuation and mortality in this population.
2. Methods
2.1. Data Source. The source of data for this study was the
National Cancer Institute’s (NCI) Surveillance Epidemiology
and End Results (SEER) cancer registry linked to Medicare
enrollment and claims data (SEER-Medicare data). This da-
tabase has been described in detail elsewhere [18]. SEER
collects and publishes cancer incidence and survival data
from 20 population-based cancer registries throughout the
United States (US) covering approximately 26% of the US
population [19]. The registries collect data on patient demo-
graphics, primary tumor site, tumor morphology and stage
at diagnosis, ﬁrst course of treatment, and follow-up for vital
status. Additional data on patterns of care and outcomes
other than survival are only available through the incorpora-
tion of Medicare claims data. In the SEER-Medicare data, for
persons age 65 years or older, 97% are eligible for Medicare,
and 93% of patients in the SEER ﬁles are matched to the
Medicare enrollment ﬁle [20]. At the time this study was
performed,theSEER-MedicarelinkageincludedallMedicare
eligible persons appearing in 16 SEER registries through
2005 and their Medicare claims for Part A (inpatient) and
Part B (outpatient and physician services) through 2006. Pa-
tients from the Greater Georgia [added in 2010] and Native
American registries [Alaska Indian, Cherokee Nation, and
Alaska Native] were not available.
2.2.PatientEligibility. Twogroupsofwomenwithmetastatic
disease were included in this study: those who were ﬁrst
diagnosed with Stage IV breast cancer between 2000 and
2005 (hereafter referred to as “incident” patients) and those
who were diagnosed with Stage 0–III breast cancer between
2000 and 2005 and who were later diagnosed with a distant
recurrence before the end of their Medicare claims (hereafter
referred to as “recurrent” patients). Patients were included
if they ﬁrst received trastuzumab after diagnosis of MBC. In
addition, we required that women be enrolled in Medicare
Parts A and B, with no health maintenance organization
(HMO) coverage for 12 months prior to diagnosis of MBC
to ensure the availability of claims information to estimate
baseline comorbidity burden. Women were excluded if they
died during the month of diagnosis or if they had less than
12 months of Medicare participation before MBC diagnosis.
In addition, because our primary aim was to evaluate
the eﬀect of CNS metastases emerging after initiation of
trastuzumab, women with CNS metastases at the time of
trastuzumab initiation were excluded from the cohort and
primary analyses. However, a sensitivity analysis was con-
ducted by adding these women back into the cohort (see
Section 2.7).
2.3. Timing of Exposures and Outcomes. International Clas-
siﬁcation of Diseases, 9th Revision, Clinical Modiﬁcation
(ICD-9-CM)procedurecodes[21]andHealthcareCommon
Procedure Coding System (HCPCS) codes [22] within Medi-
care claims were used to identify intravenous chemotherapy
agentsandtrastuzumabadministeredduringtheobservation
period. Medicare Part D (prescription drug coverage) data
were not available; consequently, antiestrogen or other oral
therapy could not be identiﬁed. For conﬁdentiality reasons,
SEER provides only the calendar month in which cancer
was diagnosed, so for incident patients, the date of MBC
diagnosis was deﬁned as the ﬁrst day of the diagnosis
month. For recurrent patients, the date of diagnosis was
deﬁned as the date of the ﬁrst Medicare claim indicating
distant recurrence. The observation period began on the day
trastuzumab was initiated (the index or baseline date).
The date of death was assigned by using the Medicare
date. In cases wherethe Medicare date wasmissing, the SEER
date was used. All other patients were assumed to be alive at
the end of the analysis period (December 31, 2006), except
for those switching from fee-for-service to HMO coverage
who were censored at the time of the change in coverage.
Discontinuation was deﬁned as a period of at least 60 days
with no trastuzumab treatment and no reinitiation, using
the ﬁrst day of the interval as the discontinuation date. As
a result, patients were not at risk of discontinuation within
60 days of the end of observation, and death was not counted
as discontinuation.
2.4. Patient Characteristics. Patients were described accord-
ing to their demographic and clinical characteristics at the
time MBC was diagnosed. Patient age at MBC diagnosis was
stratiﬁed into ﬁve groups: 66–69, 70–74, 75–79, 80–84, and
≥85. Requiring eligible patients to have at least one year
of Medicare enrollment prior to diagnosis ensured that the
minimum age in the cohort was 66 years. Race/ethnicity
was deﬁned using the SEER recoded race variable as white,
black, Hispanic, and other (which consists predominantly of
American Indian/Native Alaskan, Native Hawaiian or Other
Paciﬁc Islander, and Asian) [23].
Medicare claims for inpatient, outpatient, and physician
services were used to calculate an NCI Comorbidity Index
for each patient [24–26]. The algorithms used to identify
these conditions reﬂect the Deyo et al. [27] adaptation of
the Charlson Comorbidity Index [28] and include several
procedure codes from the Romano et al. [29] adaptation. A
weight was assigned to each condition, and the weights were
summed to obtain the index for each patient.
2.5. Identiﬁcation of Recurrence and Metastases. For recur-
rent patients, distant recurrence was identiﬁed by an ICD-
9-CM code in the medical claims for secondary cancer
(197.XX–198.XX), excluding breast (198.81, 198.82) and
lymph node (196.XX) [30, 31]. The number and location
of metastases were identiﬁed using the speciﬁc ICD-9-CMJournal of Cancer Epidemiology 3
diagnosis codes for recurrence. Based on a recent validation
study of CNS metastases in lung cancer patients, a single
occurrenceof ICD-9-CM code 198.3 was used to indicate the
presence of a metastasis to the brain or spinal cord (hereafter
referredtoasCNSmetastasis)[32].Allothermetastaseswere
identiﬁed and grouped into the following categories based
on the speciﬁc codes: Bone, Lung/Chest, Liver, and Other.
The ﬁrst occurrence within each site category was recorded
for each patient (see Section 2.6), and each was classiﬁed as
being present either at the time of trastuzumab initiation
(baseline) or afterward. Patients with more than one site of
metastasis were not identiﬁed as unique groups because of
the potentially large number of such groups.
2.6. Statistical Analysis. Cumulative incidence was estimated
using Kaplan-Meier methods to account for censoring and
death. Cumulative incidence rates were reported at 36
months when only 6% of the original cohort was still alive.
Incidence rates were estimated across all time of observation
and expressed in terms of cases per patient-month of obser-
vation.
Cox proportional hazards modeling was used to identify
factors associated with time to trastuzumab discontinuation
and time to death. Because trastuzumab therapy was a
criterion for inclusion in this study, death could not have
occurred until after trastuzumab was initiated. Therefore, to
avoid immortal time bias [33], the index (baseline) date for
these analyses was the date of the ﬁrst claim for trastuzumab.
An independent variable was included to account for the
time(indays,transformedusingthenaturallogarithm)from
MBCdiagnosistoinitialtrastuzumab,andthiswasevaluated
in sensitivity analyses.
In the models of time to discontinuation, the sites of
metastases were indicated both at baseline and as time-vary
ing covariates after baseline (i.e., reﬂecting new metastases
not present at the time of trastuzumab initiation). In addi-
tion, hospitalization (all-cause) was included as a time-
varying covariate. Other patient and tumor characteristics
were included as baseline covariates. In the models of time to
death, the covariates were the same, except for the addition
of a time-varying covariate indicating the discontinuation of
trastuzumab. Analyses were not adjusted for multiple com-
parisons.
2.7. Sensitivity Analyses. Sensitivity analyses were conducted
to test the robustness of the results to variations in model
speciﬁcation. This included adding patients with CNS
metastases diagnosed before trastuzumab initiation to the
cohort and including the presence of CNS metastases as a
baseline covariate, as well as using a delayed entry approach
to change the time scale of the models to time since MBC
diagnosis rather than time since trastuzumab initiation. The
latter approach more precisely controls for the time between
MBC diagnosis and trastuzumab initiation by only including
patientswhosurvivedthesamelengthoftimesincediagnosis
in the risk set [34].
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Figure 1: Cumulative incidence of metastases in women with
metastatic breast cancer receiving trastuzumab over 36 months.
Note: Data truncated at 36 months because only 6% of the cohort
was available for additional followup. Incidence rates estimated in
patients who were free of the particular metastasis at baseline. See
Table 2 for number at risk for each site of metastasis.
3. Results
3.1. Characteristics of Patients at Trastuzumab Initiation.
There were 562 patients who met the study inclusion criteria
(Table 1). Sixty percent were diagnosed with recurrent
disease, while the remaining patients were diagnosed with
incidentdisease.Themeanagewas76years.Bonemetastases
were present at baseline in almost half of patients (48%) with
other sites of metastasis present in 29% to 33% of patients.
The average time of observation (from start of trastuzumab
to death, the end of eligibility, or the end of observation) was
527 days. The median was 416 days, (interquartile range 199
to 712 days).
3.2.IncidenceofMetastases. Inwomenwithrecurrentdisease
(n = 336), the 5-year cumulative incidence of CNS meta-
stases after starting trastuzumab was 37% (95% CI 27–49%)
using the Kaplan-Meier estimator. In women with incident
disease (n = 226), the 5-year cumulative incidence of CNS
metastases after starting trastuzumab was 53% (95% CI 41–
67%).Thelog-ranktestfordiﬀerencesbetweentherecurrent
and incident groups was not signiﬁcant (P = 0.17).
Incidence rates for the diagnosis of new metastases were
comparable for CNS, lung/chest, and liver at approximately
14 per 1,000 patient years (Table 2 and Figure 1). The rate
for bone metastases was higher at 24 per 1,000 patient-years,
andlowerforallothersitescombinedat11per1,000patient-
years. At 24 months, the cumulative incidence of metastasis
was as follows for each site: bone (43%, 95% CI 36%–51%),
lung/chest (31%, 95% CI 25%–37%), CNS (31%, 95% CI
26%–37%), liver (25%, 95% CI 20%–31%), and other (22%,
95% CI 17%–28%).4 Journal of Cancer Epidemiology
Number at risk: 562 at baseline,
202 at 12 months, and 35 at 36 months
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Figure 2:Cumulativerateoftrastuzumabdiscontinuationinwom-
en with metastatic breast cancer. Note: Light gray bars represent
95% conﬁdence interval bands.
3.3. Trastuzumab Discontinuation. The rate of trastuzumab
discontinuation was estimated to be 37 per 1,000 patient-
months with 58% (95% CI 52%–64%) of those still alive
having discontinued by 24 months (Figure 2). In the model
of time to trastuzumab discontinuation, none of the metas-
tasespresentatbaselinewereassociatedwithdiscontinuation
(Table 3). The presence of newly identiﬁed CNS metastases
after diagnosis was associated with a 1.78-fold higher risk
of trastuzumab discontinuation (95% CI 1.11–2.87); no
other newly identiﬁed sites of metastases were associated
with discontinuation. The only other factor associated with
discontinuation was that incident patients were 35% (95%
CI 12%–52%) less likely to discontinue treatment compared
to recurrent patients. See Table 3 for full model results.
3.4. Time to Death. Median survival from the time of tras-
tuzumab initiation was 19 months (95% CI 15–22). In the
multivariate proportional hazards model of time to death,
the presence of liver metastases at baseline was associated
with a 2-fold increase in risk, while baseline lung/chest
metastases were associated with a 1.4-fold increase (Table 4).
The diagnosis of new liver and CNS metastases over the
follow-up period were associated with 2.5-fold and 2.8-
fold increases in risk, respectively. Hospitalization for any
reason and new cardiovascular disease were also strong
independent predictors of death. Finally, the discontinuation
of trastuzumab was also associated with death (HR = 2.44,
95% CI 1.90–3.15).
3.5.SensitivityAnalyses. WhenpatientswithCNSmetastases
atbaseline(timeoftrastuzumabinitiation)wereaddedtothe
cohort(n = 48),theresultsdidnotchangeinanymeaningful
way and the presence of CNS metastases was not associated
with a signiﬁcantly diﬀerent risk of discontinuation or death
(results not shown). In addition, changing the time scale of
the models to reﬂect time since diagnosis (rather than time
since trastuzumab initiation) using a delayed entry approach
also did not change the results.
4. Discussion
Based on these analyses of older women (≥66 years of age)
with MBC, the diagnosis of CNS metastases was an inde-
pendent risk factor associated both with the discontinuation
of trastuzumab and with mortality. In addition, new liver
and “other” metastases were also associated with a 2-3-fold
increased risk of death. Based on these data, the risk of
death in women taking trastuzumab who developed new
CNS metastases appeared to be comparable to new liver
metastases. This is a particularly interesting ﬁnding given the
fact that women with CNS metastases were more likely to
discontinue theirtrastuzumabtherapy, butwomenwithliver
metastases were not.
This diﬀerential in discontinuation rates by site of metas-
tasis suggests that risk of death is not the sole criterion used
to determine discontinuation. One factor that may explain
part of this diﬀerential is that, because trastuzumab does not
easily cross the blood-brain barrier, clinicians may assume
that trastuzumab is no longer eﬀective and discontinue
therapy. However, there is evidence that trastuzumab may
still be eﬀective in these patients, so it is not clear that
discontinuation is the optimal approach [35].
The related question of whether the discontinuation
of trastuzumab after CNS metastasis caused the higher
mortality risk cannot be answered from this study design.
This is because therapy discontinuation is confounded by
the clinician’s perception of the patient’s prognosis. Without
detailed clinical information, one can only approximate
prognosis using the variables available in the data (e.g.,
hospitalization, new metastases, cardiovascular disease, etc.).
This high correlation between an intervention and a patient’s
prognosis, sometimes referred to as “confounding by indica-
tion,” is the most likely explanation for the higher mortality
risk associated with trastuzumab discontinuation. In fact, a
related limitation of these analyses is that we cannot distin-
guish trastuzumab discontinuation from discontinuation of
chemotherapy because 85% of women receiving chemother-
apy who discontinued trastuzumab also discontinued their
chemotherapy at the same time.
In older women taking trastuzumab, metastases in the
CNS developed at a rate that was similar to those for other
sites (Figure 1 and Table 2). Furthermore, the linear nature
of the cumulative incidence plot for all sites of metastasis
through 36 months illustrates that, despite therapy with
trastuzumab, MBC continued to progress over time with
a fairly uniform risk of metastasis to other sites. Bone
metastases were the most common occurrence, with much
of the diﬀerence resulting from diagnoses made in the two
months after trastuzumab initiation. This may reﬂect the
availability of eﬀectivetherapyforpreventing skeletal-related
events, and therefore a higher likelihood of having medical
claims for this condition, rather than a higher incidence rate.
Figure 1 suggests that CNS metastases were more commonly
diagnosed in later in the course of metastatic disease rather
than earlier, as suggested by others [16].Journal of Cancer Epidemiology 5
Table 1: Characteristics of patients without CNS metastases at the time of starting trastuzumab for metastatic breast cancer.
Characteristic All Patients (N = 562)
Age at start of trastuzumab (years), Median (IQR) 75 (71–79)
Months from diagnosis to trastuzumab, Median (IQR) 2 (1–6)
Age category, n (%)
66–69 94 (17)
70–74 181 (32)
75–79 148 (26)
≥80 139 (25)
Race/ethnicity, n (%)
White 455 (81)
Black 62 (11)
Hispanic 23 (4)
Other 22 (4)
Year trastuzumab therapy started, n (%)
2000 19 (3)
2001 47 (8)
2002 68 (12)
2003 89 (16)
2004 119 (21)
2005 136 (24)
2006 84 (15)
Comorbidity score at start of trastuzumab, n (%)
0 495 (88)
14 5 ( 8 )
≥22 2 ( 4 )
Stage at initial diagnosis, n (%) Recurrent Stage 0–III 336 (60)
Incident Stage IV 226 (40)
ER/PR Status, n (%)
Both ER and PR positive 143 (25)
Either ER or PR positive 91 (16)
Both ER and PR negative 251 (45)
Unknown 77 (14)
Metastases at start of trastuzumab, n (%)
Bone 269 (48)
Liver 172 (31)
Lung/Chest 184 (33)
All Other 162 (29)
N o t e :I Q R :i n t e r q u a r t i l er a n g e ,E R :e s t r o g e nr e c e p t o r ,P R :p r o g e s t e r o n er e c e p t o r .
Table 2: Incidence rates for metastases by site.
Site of
metastasis
Number starting trastuzumab without
indicated metastasis Number developing indicated metastasis Incidence rate
(95% CI)
CNS 562 125 14.1 (11.9–16.9)
Bone 293 101 24.1 (19.8–29.3)
Liver 390 86 13.5 (11.0–16.7)
Lung/Chest 378 82 14.7 (11.8–18.2)
All Other 400 68 10.7 (8.5–13.6)
Note: Rates estimated over all follow-up time and reported per 1,000 person-months of follow-up.
Women who were incident metastatic patients were 35%
less likely to discontinue trastuzumab than those who were
recurrent. While this same characteristic was not associated
with a statistically signiﬁcant change in mortality, the results
suggest that continuing therapy is viewed diﬀerently in
recurrent MBC compared to incident MBC. Finally, we also
showed that many other factors aside from CNS metastases
are associated with increased mortality risk in women with
MBC, most notably hospitalization.
The incidence of CNS metastases in women receiving
trastuzumab can be challenging to identify in the litera-
ture. While many studies report cumulative proportions of
patientswhodevelop metastasesof25% to40%,mostdo not
use methods that account for the duration of follow up, and6 Journal of Cancer Epidemiology
Table 3: Adjusted model for risk of permanent discontinuation of trastuzumab.
Characteristic Adjusted HR (95% CI) P-Value
Metastases present at trastuzumab initiation
Bone 0.96 (0.72–1.27) 0.76
Liver 0.93 (0.68–1.27) 0.65
Lung/chest 0.86 (0.63–1.16) 0.32
Other 1.02 (0.74–1.40) 0.93
Diagnosed with metastases after start of trastuzumab∗
CNS 1.78 (1.11–2.87) 0.02
Bone 1.17 (0.75–1.84) 0.49
Liver 1.08 (0.66–1.78) 0.76
Lung/Chest 0.76 (0.46–1.26) 0.29
Other 1.58 (0.95–2.64) 0.08
Hospital inpatient∗ No 1.00 (ref)
Yes 1.34 (0.59–3.06)
0.49
Age at start of trastuzumab
66–69 1.00 (ref)
70–74 1.04 (0.70–1.54) 0.86
75–79 0.95 (0.63–1.44) 0.81
≥80 1.23 (0.81–1.87) 0.33
Need line above race/ethnicity White 1.00 (ref)
Non-White 1.24 (0.89–1.72)
0.20
Time from MBC diagnosis to trastuzumab initiation Per ln (days) 1.00 (0.92–1.09) 0.99
NCI comorbidity score at start of trastuzumab
01 . 0 0 ( r e f )
1 0.99 (0.62–1.60) 0.98
≥2 1.68 (0.91–3.08) 0.10
Stage at initial diagnosis Recurrent Stage 0–III 1.00 (ref)
Incident Stage IV 0.65 (0.48–0.88)
0.005
ER/PR Status
Hormone Positive 1.00 (ref)
Hormone Negative 1.05 (0.79–1.40) 0.73
Unknown 1.14 (0.76–1.72) 0.53
Note: Asterisk (∗) indicates time varying covariate. All listed covariates were included in one model. Nonwhite race includes Black, Hispanic, and Other as a
combined category. Baseline deﬁned as the date of trastuzumab initiation. Additional covariates in model that are not shown include a time-varying covariate
for new cardiovascular disease and year of trastuzumab initiation (neither of which was statistically signiﬁcant). Reference group for each metastasis covariate
is the absence of the condition (HR = 1.0).
forlossestofollow-upfromdeathandtheendofobservation
(e.g., using Kaplan-Meier or competing risk methods) [36–
38]. However, at least three studies report 1-year Kaplan-
Meier cumulative incidence estimates for CNS metastases in
women receiving trastuzumab. These estimates, 26%, 27%
and 30%, are closer to our 2-year estimate of 31% [39–41].
This suggests that the incidence of CNS metastases may be
lower in older women, a ﬁnding consistent with ﬁndings
from a large meta-analysis using competing risk methods
[42]. One other challenge in comparing our results to those
fromotherstudiesisthatmanyfocusonnewCNSmetastases
without regard to other new sites of metastasis. Hence, it is
impossible to discern whether the CNS metastases develop at
ad i ﬀerent rate than those at other sites. Therefore, in our
study, we incorporated all sites of metastases to provide a
more complete picture of their emergence over time.
There are limitations to these analyses what should be
kept in mind. First, these were analyses of observational
data. The identiﬁcation of sites of metastases was based
on diagnosis codes as recorded in administrative billing
(i.e., claims) data, which may have limited sensitivity and
speciﬁcity. In a validation study in non-small cell lung
cancer using claims data, the use of a single diagnosis code
for CNS and spinal cord metastases was associated with
100% sensitivity (i.e., all patients with CNS metastases were
correctly identiﬁed) and with 97% speciﬁcity (some false
positives were also captured) [31]. Similarly, a study by
Lamont in breast cancer showed that using diagnosis codes
for metastasis was associated with 100% sensitivity and 97%
speciﬁcity in an analysis of progression-free survival (using
clinicaltrialdataasthegoldstandard)[32].Whilesupportive
of our approach, these studies were generally small and it
is possible that the sensitivity and speciﬁcity are not as high
in our data. Importantly, other than the validation study for
CNS metastases, there is no data to estimate the sensitivity or
speciﬁcity of identifying speciﬁc sites of metastasis. Hence,
these rates should be interpreted cautiously. Furthermore, as
notedaboveregardingbonemetastases,theratesofdiagnosis
of these metastases are likely to reﬂect both screening prac-
tices as well as available interventions.Journal of Cancer Epidemiology 7
Table 4: Adjusted model for risk of death.
Characteristic Adjusted HR (95% CI) P-Value
Metastases present at trastuzumab initiation
Bone 1.17 (0.75–1.84) 0.49
Liver 2.03 (1.55–2.64) <0.001
Lung/chest 1.36 (1.04–1.78) 0.02
Other 0.72 (0.53–0.96) 0.03
Diagnosed with metastases after start of trastuzumab∗
CNS 2.49 (1.84–3.37) <0.001
Bone 1.34 (0.93–1.94) 0.12
Liver 2.72 (1.93–3.84) <0.001
Lung/Chest 1.39 (0.98–1.97) 0.07
Other 1.91 (1.31–2.78) 0.001
Discontinued trastuzumab therapy∗ No 1.00 (ref)
Yes 2.44 (1.90–3.15)
<0.001
Hospital inpatient∗ No 1.00 (ref)
Yes 7.04 (5.32–9.32)
<0.001
Age at start of trastuzumab
66–69 1.00 (ref)
70–74 1.17 (0.80–1.69) 0.42
75–79 1.17 (0.80–1.72) 0.42
≥80 1.24 (0.84–1.81) 0.28
Race/ethnicity White 1.00 (ref)
Non-White 1.21 (0.89–1.63)
0.22
Time from MBC diagnosis to trastuzumab initiation Per ln (days) 1.07 (0.98–1.15) 0.12
NCI comorbidity score at start of trastuzumab
01 . 0 0 ( r e f )
1 1.27 (0.80–2.01) 0.31
≥2 0.95 (0.48–1.85) 0.87
Cardiovascular disease∗ Yes 3.23 (2.43–4.30) <0.001
Stage at diagnosis Recurrent Stage 0–III 1.00 (ref)
Incident Stage IV 0.86 (0.66–1.10)
0.23
ER/PR Status
Hormone Positive 1.00 (ref)
Hormone Negative 1.06 (0.81–1.40) 0.67
Unknown 1.40 (0.96–2.05) 0.08
Asterisk(∗)indicatestimevaryingcovariate.Alllistedcovariateswereincludedinonemodel.NonwhiteraceincludesBlack,HispanicandOtherasacombined
category. Baseline deﬁned as the date of trastuzumab initiation. Year of trastuzumab initiation (not signiﬁcant) was also included as a covariate but results are
not shown. Discontinuation was deﬁned to be at least 60 days with no therapy. Reference group for cardiovascular disease and for each metastasis covariate is
the absence of the condition (HR = 1.0).
In addition, we did not have access to data on oral ther-
apies. While only 41% of the cohort was known to be hor-
mone positive, information about hormonal therapy that
might have been used in this subset of patients could have
aﬀected the results. Also, our data are relevant to older
women with MBC and may not reﬂect the experiences of
younger patients. Finally, our data reﬂect practice patterns
from2000through2006andmaynotreﬂectcurrentpatterns
of care.
5. Conclusion
The diagnosis of CNS metastases was associated with both
discontinuation of trastuzumab therapy as well as with
mortality. The rate of metastasis development appeared to
be linearly related to survival time and appeared comparable
among various sites of recurrence, with the possible excep-
tion of metastasis to the bone.
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